UCLA-led gene therapy approved by FDA for rare, life-threatening immune disorder

A groundbreaking gene therapy developed through a UCLA-led clinical trial has received approval from the U.S. Food and Drug Administration, offering new hope to children diagnosed with a rare and often fatal immune disorder. The treatment, marketed as Kresladi, is the first FDA-approved gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a genetic condition that […]A groundbreaking gene therapy developed through a UCLA-led clinical trial has received approval from the U.S. Food and Drug Administration, offering new hope to children diagnosed with a rare and often fatal immune disorder. The treatment, marketed as Kresladi, is the first FDA-approved gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a genetic condition that […]